The Projects of this Program have research strategies that variously involve genome-wide analysis of cancer cell epigenomes and transcriptomes and the use of screens involving genome editing. The primary objective of the Functional Epigenetics Core is to support the PO1 Projects with expertise in epigenetics approaches and CRISPR screens.
The specific aims of the Functional Epigenetics Core achieve this by providing the Program with the experimental and computational capabilities required to meet these essential programmatic needs. The Core is directed by Dr. Henry W. Long, an experienced, highly productive laboratory scientist based at the Center for Functional Cancer Epigenetics at the Dana Farber Cancer Institute in Boston. Dr. Long has a history of innovation in providing the critical resources and services to research projects in prostate and other cancers over the past 5 years at the CFCE. The Core is co-led by Dr. X Shirley Liu, a highly cited and productive computational biologist and biostatistician also based at the Dana Farber Cancer Institute. Dr. Liu has a very strong track record of innovation in epigenetics and CRISPR screening.
The Aims are 1) Support CRISPR screening approaches; 2) Provide capabilities and resources for performing complex epigenetic experiments; 3) Analysis and integration of epigenetic datasets; 4) Data sharing and management.
The primary objective of the Functional Epigenetics Core is to support the PO1 Projects with expertise in epigenetics approaches and CRISPR screens. The specific aims of the Functional Epigenetics Core achieve this by providing the Program with the experimental and computational capabilities required to meet these essential programmatic needs. The Core is directed by Dr. Henry W. Long, a highly productive laboratory scientist, and by Dr. X Shirley Liu, a renowned computational biologist and biostatistician with a track record of innovation in epigenetics and CRISPR screening.
|Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201|
|Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432|
|Chen, Sen; Cai, Changmeng; Sowalsky, Adam G et al. (2018) BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res 78:5203-5215|
|Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167|
|Beshiri, Michael L; Tice, Caitlin M; Tran, Crystal et al. (2018) A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 24:4332-4345|
|Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104|
|Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :|
|Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216|
|Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470|
|Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19|
Showing the most recent 10 out of 90 publications